Buradagunta, Christopher Staffi
Arsang-Jang, Shahram
Massat, Ben
Thapa, Bicky
Patek, Victoria
D’Souza, Anita http://orcid.org/0000-0002-1092-5643
Auer, Paul
Urrutia, Raul
Janz, Siegfried http://orcid.org/0000-0002-2229-5511
Dhakal, Binod http://orcid.org/0000-0002-4377-9742
Hari, Parameswaran http://orcid.org/0000-0002-8800-297X
Dong, Jing http://orcid.org/0000-0001-9856-5963
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K01 HL164972)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA151354)
Article History
Received: 18 September 2023
Revised: 23 October 2023
Accepted: 27 October 2023
First Online: 2 November 2023
Competing interests
: AD reports institutional research funding from Abbie, Caelum, Janssen, Novartis, Prothena, Sanofi, TeneoBio; advisory board participation fees from BMS, Janssen, Pfizer, and Prothena; consulting fees from Janssen and Prothena.